Dimension Therapeutics (DMTX) Tops Q1 EPS by 19c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/5/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. SWKS
7. ANET
8. SPY
9. XYZ
10. CVS

Go back to Dimension Therapeutics (DMTX) Tops Q1 EPS by 19c

Dimension Therapeutics Reports Recent Corporate Progress and First Quarter 2016 Financial Results

May 12, 2016 9:03 AM EDT

Expanded inherited metabolic disease (IMD) portfolio; New programs address citrullinemia type 1, phenylketonuria (PKU), and Wilson disease

Expect to file INDs for lead IMD product candidates, DTX301 for OTC deficiency and DTX401 for GSDIa, both in second half 2016; Initiate dosing for DTX301 for OTC deficiency in second half 2016

Ongoing Phase 1/2 trial of DTX101 for hemophilia B on plan to report initial data in 2H 2016

CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ: DMTX), a biopharmaceutical company advancing novel,... More